Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad). Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...
The Malaysian government has approved a government-use compulsory license which would allow the import of generic versions of Gilead’s patented hepatitis C drug, Sovaldi. The decision was made in August but has become public this week. On September 14, the Malaysian cabinet approved for this license. The move will make generic and cheaper versions of the same drug, which has been sold globally at $1000 per pill. The low-cost versions will now be available
Friday, June 2, 2017 News Recap Boomers Should Be Tested Most of the HepC-related news last week from various agencies in the USA stressed the fact that Baby Boomers should be tested and that hepatitis C is a hidden and growing danger (GET TESTED: 1 in 30 baby boomers have Hepatitis C, 70 percent are unaware). In Canada voices of dissent can be heard regarding the federal government’s asinine decision NOT to test Boomers. The decision was based ...
MUMBAI: Remember Ron the rodeo cowboy from the Oscar-winning film Dallas Buyers Club? The biopic portrayed the story of Ron Woodroof, an AIDS patient in the mid-1980s who signed up for an experimental AIDS treatment movement. He smuggled unapproved drugs into Texas for treating his symptoms and distributed them to fellow patients at a time when the disease was highly stigmatised. There’s now an Australian parallel, of sorts, with an Indian twist. Australi
California-headquartered Gilead Sciences has warned against the use of generic versions of its blockbuster Hepatitis C drugs procured by patients directly through “buyers clubs.” A disruptive phenomenon, dozens of buyers clubs have mushroomed in recent years that enable supply of generic lifesaving medicines to thousands of patients afflicted with the fatal liver ailment. In its latest May 9 regulatory filings in Form 10K at the US Securities Exchange Com
Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported last week at the International Liver Congress in Amsterdam. Dr James Freeman, an Australian general practitioner based in Hobart, Tasmania, was reporting on the outcomes of people with hepatitis C who imported generic versions of direct-acting antivirals manufactured in India and elsewhere
Resistance to high prices for hepatitis C drugs is ongoing as five new challenges against patents have been filed in India and Argentina, according to sources. Those challenges aim at allowing the production and distribution of affordable generic versions of new hepatitis C medicines (direct-acting antivirals). According to a Médecins Sans Frontières (MSF, Doctors Without Borders) press release, on 13 February the Initiative for Medicines, Access & Kn
Friday, December 9, 2016 News Recap There was not much news on the LOCAL front this past week except for an excellent speech written and given at a World AIDS Day rally in Vancouver by Daryl Luster (We Have Not Abandoned the Principles or Communities We Serve, Neither Should PHAC), and an update on the status of persons with disabilities in BC. Because the government is not treating everyone with HepC, we have developed an aging population where many...
This is a very interesting article about taking generics and how to get monitored and pay for it. In Canada, we are finding workarounds, but it is not easy! (CD) A Dunedin Hospital staff member has criticised her employer, the Southern District Health Board, for refusing medical support for hepatitis C sufferers who are legally importing life-changing drugs. Tina Hill, an anaesthetic technician, cured herself of the disease a year ago by purchasing a
Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool (MPP), a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries. Under the agreement, announced yesterday, November 28, Mylan will produce and market a generic version of Bristol-Myers Squibb’s Daklinza (daclatasvir). The generic drug will be distributed in 112 low and middle income countries. Source: http://www.li